XOMA Royalty (NASDAQ:XOMA) Hits New 12-Month High – Still a Buy?

XOMA Royalty Corporation (NASDAQ:XOMA) shares hit a new 52-week high on Wednesday . The stock traded as high as $44.01 and last traded at $43.89, with a volume of 144744 shares trading hands. The stock had previously closed at $43.85.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on XOMA. Weiss Ratings raised shares of XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, May 29th. Zacks Research raised shares of XOMA Royalty from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 8th. HC Wainwright downgraded shares of XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 price objective for the company. in a research report on Thursday, April 30th. Lucid Cap Mkts cut XOMA Royalty from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Finally, Benchmark downgraded XOMA Royalty from a “buy” rating to a “hold” rating in a research report on Friday, May 22nd. One equities research analyst has rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $53.75.

XOMA Royalty Stock Performance

The company has a debt-to-equity ratio of 0.96, a current ratio of 3.59 and a quick ratio of 3.59. The stock’s 50-day moving average price is $41.93 and its 200-day moving average price is $33.32. The company has a market cap of $550.38 million, a P/E ratio of 27.96 and a beta of 0.86.

XOMA Royalty (NASDAQ:XOMA) last released its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). The business had revenue of $12.32 million for the quarter, compared to the consensus estimate of $13.91 million. XOMA Royalty had a return on equity of 12.56% and a net margin of 53.46%. Equities analysts anticipate that XOMA Royalty Corporation will post 0.9 EPS for the current year.

Institutional Investors Weigh In On XOMA Royalty

Several institutional investors have recently made changes to their positions in the stock. State of Alaska Department of Revenue acquired a new stake in XOMA Royalty during the fourth quarter worth approximately $27,000. Russell Investments Group Ltd. raised its holdings in XOMA Royalty by 3,436.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 756 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in XOMA Royalty by 203.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 1,523 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of XOMA Royalty by 13.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 543 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in shares of XOMA Royalty during the 2nd quarter worth $116,000. 95.92% of the stock is currently owned by institutional investors.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.